---
accession : E-MEXP-3192
platform  : A-AGIL-28
pathway   : EGFR
cells     : SKBR3 breast cancer cells
treatment : 100 nM lapatinib
effect    : inhibiting
hours     : 12

control   :
    - CONTROL_12H_A
    - CONTROL_12H_B
    - CONTROL_12H_C
perturbed :
    - LAP_12H_A
    - LAP_12H_B
    - LAP_12H_C
...
